Market Intelligence, Clinical Progress, and High-Purity Reagents for MPS IIIB (Sanfilippo Syndrome Type B) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NAGLU drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NAGLU Recombinant Protein (WT & Pathogenic Mutants) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed for native M6P glycosylation. Includes key variants R74C, R297X, S631L for rescue assays. |
View NAGLU Products |
| Gene Delivery | NAGLU Premade ORF / Lentivirus Full-length human NAGLU ORF for stable cell line generation (fibroblast/iPSC). |
View NAGLU Products |
| Reference Antibody | Anti-NAGLU Recombinant Antibody High-affinity rabbit monoclonal for PK/PD, ADA, and immunogenicity assays. |
View NAGLU Products |
| Validator | NAGLU siRNA Set For knockdown and assay specificity verification. |
View NAGLU Products |
| Related Target: SGSH | SGSH (N-sulfoglucosamine sulfohydrolase) MPS IIIA (Sanfilippo A) target. Same heparan sulfate degradation pathway. |
View SGSH Products |
| Related Target: HGSNAT | HGSNAT (Heparan-alpha-glucosaminide N-acetyltransferase) MPS IIIC target. Lysosomal enzyme in same catabolic cascade. |
View HGSNAT Products |
| Related Target: GNS | GNS (N-acetylglucosamine-6-sulfatase) MPS IIID (Sanfilippo D) target. Completes pathway coverage. |
View GNS Products |
| Related Target: M6PR | M6PR (Mannose-6-Phosphate Receptor) CI-M6PR/IGF2R for lysosomal targeting and cellular uptake assays. |
View M6PR Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mannose-6-Phosphate (M6P) Uptake & Lysosomal Trafficking | HEK293-expressed NAGLU with native glycosylation; Biotin- or His-tagged formats for quantitative uptake FACS/ICC. |
| Pathogenic Mutant Chaperone Screening | Site-directed mutant NAGLU proteins (>95% purity, Sequence Verified) for high-throughput chaperone binding and refolding assays. |
| Cross-species Preclinical Evaluation (Mouse / Cyno) | Human, Mouse, and Cynomolgus NAGLU orthologs available with >95% purity and matched theoretical MW. |
| Immunogenicity & PK Assessment | Anti-NAGLU reference antibody plus WT/mutant antigen standards for ADA method development. |
| Assay Specificity Controls | Validated siRNA included for knockdown verification in iPSC/fibroblast reporter lines. |
Live NAGLU R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NAGLU therapeutics is intensifying, with major players shifting focus from traditional ERT to AAV-based gene therapy and CNS-targeted delivery platforms. First-generation enzyme replacement strategies struggle with blood-brain barrier (BBB) penetrance, driving the next wave of R&D toward intrathecal AAV administration, brain-penetrant capsids, and pharmacological chaperones for amenable mutations. The pipeline increasingly features fusion proteins engineered with BBB-crossing modules (e.g., anti-TfR) and gene therapy vectors that achieve durable CNS expression with reduced liver toxicity. Substrate reduction and hematopoietic stem cell gene therapy also remain active areas of investigation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| AAV Gene Therapy | REGENXBIO, Abeona, uniQure | MPS IIIB (CNS) | Stable Cell Line Construction (Need NAGLU Lentivirus/ORF for transduction efficiency) |
| ERT (Enzyme Replacement) | BioMarin, JCR Pharma, emerging biotechs | MPS IIIB (Systemic / CNS) | Enzymatic Activity & M6P Uptake (Need high-purity WT protein, endotoxin controlled) |
| Brain-Penetrant Fusion Proteins | Denali Therapeutics, JCR Pharma | Neuropathic MPS IIIB | BBB Transcytosis Assays (Need high-purity NAGLU and TfR/M6PR controls) |
| Chaperone Therapy | Amicus, academic consortia | MPS IIIB (mutation-specific) | Mutant Binding & Thermal Shift (Need pathogenic mutant NAGLU proteins) |
| Substrate Reduction | Takeda, Zymenex | MPS IIIB (adjunct) | Lysosomal Burden Assay (Need cellular NAGLU overexpression/knockdown systems) |
| HSCT Gene Therapy | Academic consortia | Pediatric Neurodegeneration | Cell Line Validation (Lentivirus ORF stable expression) |
Key Pathogenic Mutations in NAGLU (MPS3B)
| Mutation | dbSNP | Effect on Enzyme |
|---|---|---|
| in MPS3B; no enzyme activity; synthesizes a polypeptide with a molecular size si | UniProt P54802 VAR_054699 | Complete loss of activity |
| in MPS3B; decreases the enzyme activity markedly | rs1460260015 | Marked reduction of activity |
| in MPS3B | rs867910252 | Pathogenic, likely reduced activity |
Related Target Expansion
Beyond the core Sanfilippo pathway, TarMart also provides reagents for M6PR (mannose-6-phosphate receptor) and TFRC (transferrin receptor), which are essential for BBB-crossing fusion protein development and lysosomal uptake assays. These cross-linked targets empower comprehensive preclinical and translational studies for next-generation NAGLU therapeutics.